Izotropic Successfully Extends Exclusive Global License Agreement for Innovative Breast CT Technology until 2027

ID: 1556368
recent pressrelease next pressrelease

(businesspress24) - VANCOUVER, BC - February 26, 2020 - Izotropic Corporation (Izotropic or the Company) (CSE: IZO) (OTC US: IZOZF) (FRA: 1R3) The Company is pleased to announce that it has extended the terms of its exclusive global License Agreement with The Regents of the University of California.

The amendments under the revised exclusive global License Agreement relate to the formal Commercialization Plan of breast CT technology developed at UC Davis Medical Center in Sacramento, CA. Due to unforeseen delays with patent prosecutions and completing important patent applications and filings, there was mutual desire by the parties to negotiate an extension.

The Company now has until January 2027 to execute on the terms agreed to under the Commercialization Plan and expects to meet the terms of the Commercialization Plan under the Licensing Agreement well before this date. In consideration of this extension, a nominal payment of $20,000 per annum will be made until commercialization terms are completed.

Extending the commercialization terms and timeline is a material development for the Company and we wish to acknowledge the support and cooperation provided by the Regents of the University of California and UC Davis.


Robert Thast
Chief Executive Officer

About Izotropic Corp.

Izotropic Corporation (the Company) and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Companys breast CT imaging platform.

Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, fully funded $2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Phone: 1-833-IZOCORP
Email: info(at)izocorp.com
Website: izocorp.com

More information:

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: irw
print pressrelease  send to a friend  

Date: 02/26/2020 - 07:35
Language: English
News-ID 1556368
Character count: 2435
Firma: Izotropic Corporation
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Wien


Number of hits: 418


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 148

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.


[ more PressReleases ][ RSS-Feed ]